Drug Trial Radar · NCT04312347
Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels
Last checked: Nov 19, 2026Latest source record: Aug 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
151
Actual
Start
Sep 6, 2019
Primary completion
May 1, 2021
Study completion Jun 30, 2021
Sponsor
- Lead sponsor
- Nalagenetics Pte LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 18, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen levels.
Conditions
- ER+ Breast Cancer
Interventions
Tamoxifen dose adjustmentDrug
Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effects of genotype and phenotype of CYP2D6 on plasma and serum concentration of tamoxifen and its metabolitesTime frame: 8 weeks after initial tamoxifen intake
- Effects of dose recommendation of tamoxifen based on CYP2D6 genotyping results on endoxifen levelsTime frame: 8 weeks after dose recommendation
- Frequencies of CYP2D6 alleles in female Indonesian populationTime frame: Baseline, pre-intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MRCCC Siloam Hospital Semanggi
Jakarta, DKI Jakarta, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.